

## Copper-catalyzed 1,6-conjugate addition of *para*-quinone methides with diborylmethane

Xin Li,<sup>a</sup> Guoliang Gao,<sup>a</sup> Songtao He,<sup>a</sup> and Qiuling Song <sup>\*a,b</sup>

<sup>a</sup>Institute of Next Generation Matter Transformation, College of Materials Science & Engineering, Huaqiao University, 668 Jimei Blvd, Xiamen 361021, Fujian, China.

<sup>b</sup>State Key Laboratory of Organometallic Chemistry and Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.

<sup>\*</sup>qsong@hqu.edu.cn

## Supporting Information

### Table of Contents


I. General Information .....	1
II. Preparation of Materials .....	2
2.1. Synthesis of <i>p</i> -Quinone Methide Substrates .....	2
2.2. Synthesis of <i>p</i> -Quinone Methide <b>1ai</b> and <b>4a</b> .....	2
2.3. Synthesis of <i>p</i> -Quinone Methide <b>4b</b> .....	2
2.4. Synthesis of Diborylmethane <b>2a</b> .....	2
III. Screening of Reaction Conditions .....	3
IV. 1,6-Conjugate Addition of Diborylmethane .....	6
V. Synthesis of compound <b>7</b> .....	15
VI. Synthesis of compound <b>9</b> .....	15
VII. NMR Spectra.....	16

### I. General Information

All air or moisture sensitive reactions were conducted in oven-dried glassware under nitrogen atmosphere using dry solvents. Anhydrous toluene were freshly distilled from sodium. Unless otherwise stated, chemicals and reagents were used as received. Flash column chromatography was performed over silica gel (200-300 mesh) purchased from *Qindao Bangkai Co., China*. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV 500 MHz NMR spectrometer using residue solvent peaks as an internal standard (<sup>1</sup>H NMR: CHCl<sub>3</sub> at 7.26 ppm, <sup>13</sup>C NMR: CDCl<sub>3</sub> at 77.0 ppm). HRMS were recorded on an Agilent 6545 Q-TOF LC/MS instrument with electrospray ionization (ESI) technique.


## II. Preparation of Materials

### 2.1. Synthesis of *p*-Quinone Methide Substrates




*p*-Quinone methide substrates **1a–1ah**, **1aj** were synthesized according to the literature reported procedure.<sup>1</sup> They are known compounds.

### 2.2. Synthesis of *p*-Quinone Methide **1ai** and **4a**




*p*-Quinone methide **1ai** and **4a** were synthesized according to the literature reported procedure.<sup>2</sup> They are known compounds.

### 2.3. Synthesis of *p*-Quinone Methide **4b**



*p*-Quinone methide **4b** was synthesized according to the literature reported procedure.<sup>3</sup> It is a known compound.

### 2.4. Synthesis of Diborylmethane **2a**



<sup>1</sup> D. Richter, N. Hampel, T. Singer, A. R. Ofial, H. Mayr, *Eur. J. Org. Chem.* **2009**, *19*, 3203.


<sup>2</sup> Z.-Q. Liu, P.-S. You, L.-D. Zhang, D.-Q. Liu, S.-S. Liu, X.-Y. Guan, *Molecules* **2020**, *25*, 539.

<sup>3</sup> S. Gao, X. Xu, Z. Yuan, H. Zhou, H. Yao, A. Lin, *Eur. J. Org. Chem.* **2016**, 3006.

Diborylmethane **2a** was synthesized according to the literature reported procedure.<sup>4</sup> It is a known compound.

### III. Screening of Reaction Conditions

**Table S1. Screening of Solvents and Copper Catalysts**



entry	solvent	[Cu]	yield (%)
1	THF	Cu(OTf) <sub>2</sub>	trace
2	MeCN	Cu(OTf) <sub>2</sub>	trace
3	dioxane	Cu(OTf) <sub>2</sub>	20
4	hexane	Cu(OTf) <sub>2</sub>	trace
5	toluene	Cu(OTf) <sub>2</sub>	84
6	toluene	CuSCN	trace
7	toluene	CuCl	67
8	toluene	CuBr	< 5
9	toluene	CuI	< 5
10	toluene	CuTc	44
11	toluene	Cu <sub>2</sub> O	trace
12	toluene	CuCl <sub>2</sub>	30
13	toluene	CuBr <sub>2</sub>	trace
14	toluene	CuF <sub>2</sub>	trace
15	toluene	Cu(NO <sub>3</sub> ) <sub>2</sub>	36
16	toluene	Cu(acac) <sub>2</sub>	49
17	toluene	Cu(OAc) <sub>2</sub>	73
18	toluene	none	0
19 <sup>a</sup>	toluene	Cu(OTf) <sub>2</sub>	95
20 <sup>b</sup>	toluene	Cu(OTf) <sub>2</sub>	93
21 <sup>c</sup>	toluene	Cu(OTf) <sub>2</sub>	16

a: the reaction was performed at 50 °C

b: the reaction was performed at 60 °C

c: the reaction was performed at rt

<sup>4</sup> X. Liu, T. M. Deaton, F. Haeffner, J. P. Morken, *Angew. Chem., Int. Ed.* **2017**, *56*, 11485.

**Table S2. Screening of Ligands**

<hr/>			
87%	97%	96%	93%
66%	96%	89%	73%
28%	99%	92%	49%
8%	trace (trace <sup>a</sup> )	trace	trace
trace	trace	trace	none 0%

a: 5 mol% of ligand was used

**Table S3. Screening of Base and Other Reaction Conditions**

entry	base	T (°C)	t (h)	yield (%)
1	LiO <sup>t</sup> Bu	50	16	98
2	NaO <sup>t</sup> Bu	50	16	69
3	KO <sup>t</sup> Bu	50	16	97
4	LiOMe	50	16	77
5	NaOMe	50	16	17
6	LiOH	50	16	50
7	KF	50	16	19
8	Cs <sub>2</sub> CO <sub>3</sub>	50	16	64
9	LiO <sup>t</sup> Bu	60	16	94
10	LiO <sup>t</sup> Bu	40	20	89
11	LiO <sup>t</sup> Bu	rt	20	15
12	LiO <sup>t</sup> Bu	50	12	93
13	LiO <sup>t</sup> Bu	50	8	82
14 <sup>a</sup>	LiO <sup>t</sup> Bu	50	16	trace
15 <sup>b</sup>	NaO <sup>t</sup> Bu	50	16	0
16 <sup>b</sup>	KO <sup>t</sup> Bu	50	16	0


a: The reaction was performed under air b: Without Cu(OTf)<sub>2</sub> and P<sup>t</sup>Bu<sub>3</sub>

**Table S4. Screening of the Equivalents of Catalyst/Ligand/Base**

entry	x	y	z	yield (%)
1	5	5	2	78
2	5	10	2	75
3	10	10	2	99
4	10	20	2	97
5	10	10	1	66
6	10	10	1.5	96
7	10	10	2.5	93
8 <sup>a</sup>	10	10	2	43
9 <sup>b</sup>	10	10	2	92


a: 1.0 equiv of **2a** was used b: 2.0 equiv of **2a** was used

#### IV. 1,6-Conjugate Addition of Diborylmethane



An oven-dried Schlenk tube equipped with a Teflon sealed cap was charged with  $\text{Cu}(\text{OTf})_2$  (1.8 mg, 0.005 mmol, 10 mol%),  $\text{LiO}'\text{Bu}$  (8.0 mg, 0.1 mmol, 2.0 equiv), *p*-quinone methide substrates (0.05 mmol) and a stir bar. Then a solution of diboryl methane (33.5 mg, 0.125 mmol, 2.5 equiv) and  $\text{P}'\text{Bu}_3$  (15  $\mu\text{L}$ , 10% in pentane) in anhydrous toluene (0.5 mL) was added to the tube. The tube was degassed and refilled with nitrogen for 3 times, sealed, and then heated at 50 °C for 16 hours. The reaction was quenched with saturated  $\text{NH}_4\text{Cl}$  and the aqueous layer was extracted with ethyl acetate ( $3 \times 20$  mL). The combined organic layers were dried with  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to afford the pure product.

**2,6-di-*tert*-butyl-4-(1-(4-methoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3a)**




**$^1\text{H NMR}$**  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.26 (d,  $J = 8.7$  Hz, 2H), 7.12 (s, 2H), 6.84 (d,  $J = 8.7$  Hz, 1H), 5.03 (s, 1H), 4.18 (t,  $J = 8.6$  Hz, 1H), 3.79 (s, 3H), 1.61 (d,  $J = 8.6$  Hz, 2H), 1.45 (s, 18H), 1.08 (s, 6H), 1.07 (s, 6H).

**$^{13}\text{C NMR}$**  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  157.6, 151.8, 139.6, 137.3, 135.3, 128.4, 124.1, 113.5, 82.9, 55.2, 45.9, 34.3, 30.3, 24.57, 24.56.

**$^{11}\text{B NMR}$**  (160 MHz,  $\text{CDCl}_3$ )  $\delta$  34.26.

**HRMS:** (ESI $^+$ ) [M+Na] $^+$  calcd for  $\text{C}_{29}\text{H}_{43}\text{BO}_4\text{Na}$ : 489.3147, found: 489.3145.

**2,6-di-*tert*-butyl-4-(1-(4-fluorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3b)**




**$^1\text{H NMR}$**  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.28 – 7.23 (m, 2H), 7.07 (s, 2H), 6.98 – 6.92 (m, 2H), 5.03 (s, 1H), 4.18 (t,  $J = 8.6$  Hz, 1H), 1.58 (d,  $J = 8.6$  Hz, 2H), 1.42 (s, 18H), 1.05 (s, 12H).

**$^{13}\text{C NMR}$**  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  161.1 (d,  $J = 243.0$  Hz), 151.9, 142.9 (d,  $J = 3.1$  Hz), 136.9, 135.4, 128.9 (d,  $J = 7.8$  Hz), 124.0, 114.8 (d,  $J = 20.9$  Hz), 83.0, 45.9, 34.3, 30.3, 24.6, 24.5.

**$^{11}\text{B NMR}$**  (160 MHz,  $\text{CDCl}_3$ )  $\delta$  33.51.

**HRMS:** (ESI $^+$ ) [M+Na] $^+$  calcd for  $\text{C}_{28}\text{H}_{40}\text{FO}_3\text{Na}$ : 477.2947, found: 477.2953.

**2,6-di-*tert*-butyl-4-(1-(4-chlorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3c)**



**$^1\text{H NMR}$**  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.24 (s, 4H), 7.06 (s, 2H), 5.04 (s, 1H), 4.17 (t,  $J = 8.6$  Hz, 1H), 1.57 (d,  $J = 8.6$  Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.06 (s, 6H).


**$^{13}\text{C NMR}$**  (125 MHz,  $\text{CDCl}_3$ )  $\delta$  152.0, 145.8, 136.4, 135.5, 131.3,

128.9, 128.2, 124.1, 83.1, 46.0, 34.3, 30.3, 24.58, 24.55.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.79.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>40</sub>ClBO<sub>3</sub>Na: 493.2651, found: 493.2655.

**4-(1-(4-bromophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-2,6-di-*tert*-butylphenol (3d)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38 (d, *J* = 8.4 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 2H), 7.06 (s, 2H), 5.04 (s, 1H), 4.16 (t, *J* = 8.5 Hz, 1H), 1.57 (d, *J* = 8.5 Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.06 (s, sH).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 152.0, 146.4, 136.3, 135.5, 131.1, 129.3, 124.1, 119.3, 83.1, 46.1, 34.3, 30.3, 24.57, 24.56.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.18.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>40</sub>BrBO<sub>3</sub>Na: 537.2146, found: 537.2152.

**4-(1-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)benzoate (3e)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.95 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.07 (s, 2H), 5.04 (s, 1H), 4.25 (t, *J* = 8.5 Hz, 1H), 3.90 (s, 3H), 1.61 (d, *J* = 8.5 Hz, 2H), 1.41 (s, 18H), 1.05 (s, 6H), 1.05 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 167.2, 152.7, 152.0, 136.1, 135.5, 129.6, 127.61, 127.57, 124.1, 83.1, 51.9, 46.7, 34.3, 30.3, 24.6,

24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 35.11.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>43</sub>BO<sub>5</sub>Na: 517.3096, found: 517.3093.

**4-(1-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)benzonitrile (3f)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.56 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.04 (s, 2H), 5.08 (s, 1H), 4.24 (t, *J* = 8.5 Hz, 1H), 1.59 (dd, *J* = 8.5, 3.2 Hz, 2H), 1.42 (s, 18H), 1.05 (s, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 152.9, 152.2, 135.7, 135.3, 132.1, 128.3, 124.1, 119.2, 109.4, 83.2, 46.7, 34.3, 30.3, 24.6, 24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.57.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>BNO<sub>3</sub>Na: 484.2993, found: 484.2997.

**2,6-di-*tert*-butyl-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(trifluoromethyl)phenyl)ethylphenol (3g)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.53 (d, *J* = 8.1 Hz, 2H), 7.42 (d, *J* = 8.1 Hz, 2H), 7.09 (s, 2H), 5.06 (s, 1H), 4.25 (t, *J* = 8.6 Hz, 1H), 1.62 (dd, *J* = 4.3, 2.1 Hz, 2H), 1.43 (s, 18H), 1.06 (s, 6H), 1.05 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 152.1, 151.5, 135.8, 135.6, 127.9 (q, *J* = 31.6 Hz), 127.8, 125.1 (q, *J* = 3.7 Hz), 124.4 (q, *J* = 273.4 Hz), 124.1, 83.1, 46.5, 34.4, 30.3, 24.54, 24.52.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.81.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>BF<sub>3</sub>O<sub>3</sub>Na: 527.2915, found: 527.2924.

**2,6-di-*tert*-butyl-4-(1-(4-nitrophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethylphenol (3h)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 8.14 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 7.05 (s, 2H), 5.09 (s, 1H), 4.30 (t, *J* = 8.5 Hz, 1H), 1.62 (d, *J* = 8.5 Hz, 1H), 1.42 (s, 18H), 1.06 (s, 6H), 1.06 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 155.2, 152.3, 146.1, 135.8, 135.2, 128.3, 124.1, 123.5, 83.2, 46.5, 34.4, 30.3, 24.57, 24.55.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.52.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>40</sub>BN<sub>1</sub>O<sub>5</sub>Na: 504.2892, found: 504.2896.

### 2,6-di-tert-butyl-4-(1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3i)




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.33 (dd, *J* = 8.1, 1.5 Hz, 2H), 7.27 (d, *J* = 8.1 Hz, 1H), 7.18 – 7.13 (m, 1H), 7.12 (s, 2H), 5.02 (s, 1H), 4.21 (t, *J* = 8.7 Hz, 1H), 1.62 (d, *J* = 8.7 Hz, 2H), 1.43 (s, 18H), 1.06 (s, 6H), 1.05 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.8, 147.2, 136.9, 135.3, 128.1, 127.5, 125.6, 124.2, 82.9, 46.7, 34.3, 30.3, 24.54, 24.53.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.72.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>41</sub>BO<sub>3</sub>Na: 459.3041, found: 459.3049.

### 4-(1-([1,1'-biphenyl]-4-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-2,6-di-tert-butylphenol (3j)




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.63 – 7.56 (m, 2H), 7.52 (d, *J* = 8.3 Hz, 2H), 7.43 (dd, *J* = 8.3, 7.0 Hz, 2H), 7.40 (d, *J* = 8.3 Hz, 2H), 7.36 – 7.31 (m, 1H), 7.16 (s, 2H), 5.03 (s, 1H), 4.25 (t, *J* = 8.6 Hz, 1H), 1.65 (d, *J* = 8.6 Hz, 2H), 1.44 (s, 18H), 1.06 (s, 6H), 1.05 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.9, 146.5, 141.2, 138.5, 136.8, 135.4, 128.6, 127.9, 126.93, 126.88, 126.86, 124.2, 83.0, 46.4, 34.4, 30.3, 24.6, 24.5.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.72.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>34</sub>H<sub>45</sub>BO<sub>3</sub>Na: 535.3354, found: 535.3360.

### 2,6-di-tert-butyl-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-tolyl)ethyl)phenol (3k)




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.21 (d, *J* = 8.1 Hz, 2H), 7.12 (s, 2H), 7.08 (d, *J* = 8.1 Hz, 2H), 5.00 (s, 1H), 4.17 (t, *J* = 8.7 Hz, 1H), 2.31 (s, 3H), 1.60 (dd, *J* = 8.7, 2.6 Hz, 2H), 1.43 (s, 18H), 1.06 (s, 6H), 1.04 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.8, 144.4, 137.0, 135.2, 134.9, 128.8, 127.3, 124.1, 82.9, 46.3, 34.3, 30.3, 24.6, 24.5, 20.9.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.27.

**HRMS:** (ESI<sup>+</sup>) [M+H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>44</sub>BO<sub>3</sub>: 451.3378, found: 451.3388.

### 2,6-di-tert-butyl-4-(1-(4-(tert-butyl)phenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3l)




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.28 (d, *J* = 8.5 Hz, 2H), 7.24 (d, *J* = 8.5 Hz, 2H), 7.14 (s, 2H), 5.00 (s, 1H), 4.15 (t, *J* = 8.7 Hz, 1H), 1.61 (d, *J* = 8.7 Hz, 2H), 1.43 (s, 18H), 1.30 (s, 9H), 1.03 (s, 6H), 1.00 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.8, 148.3, 144.3, 136.9, 135.2, 127.0, 125.0, 124.2, 82.9, 46.4, 34.32, 34.26, 31.4, 30.3, 24.6, 24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.91.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>49</sub>BO<sub>3</sub>Na: 515.3667, found: 515.3662.

**2,6-di-*tert*-butyl-4-(1-(4-ethoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3m)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.21 (d, *J* = 8.7 Hz, 2H), 7.09 (s, 2H), 6.81 (d, *J* = 8.7 Hz, 2H), 5.00 (s, 1H), 4.14 (t, *J* = 8.6 Hz, 1H), 4.01 (q, *J* = 7.0 Hz, 2H), 1.58 (d, *J* = 8.6 Hz, 2H), 1.42 (s, 18H), 1.40 (t, *J* = 7.0 Hz, 3H), 1.05 (s, 6H), 1.04 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 156.9, 151.7, 139.4, 137.4, 135.3, 128.4, 124.1, 114.2, 82.9, 63.4, 45.9, 34.3, 30.33, 24.6, 24.6, 14.9.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.70.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>45</sub>BO<sub>3</sub>Na: 503.3303, found: 503.3308.

**2,6-di-*tert*-butyl-4-(1-(4-(dimethylamino)phenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3n)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.19 (d, *J* = 8.7 Hz, 2H), 7.11 (s, 2H), 6.69 (d, *J* = 8.7 Hz, 2H), 4.97 (s, 1H), 4.11 (t, *J* = 8.7 Hz, 1H), 2.90 (s, 6H), 1.58 (dd, *J* = 8.7, 1.2 Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.03 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.7, 148.9, 137.5, 136.1, 135.1, 127.9, 124.1, 113.0, 82.8, 45.8, 41.0, 34.3, 30.3, 24.7, 24.6, 24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 34.05.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>46</sub>BNO<sub>3</sub>Na: 502.3463, found: 502.3468.

**2,6-di-*tert*-butyl-4-(1-(4-(diphenylamino)phenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3o)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.26 – 7.18 (m, 6H), 7.12 (s, 2H), 7.09 – 7.04 (m, 4H), 7.04 – 7.00 (m, 2H), 6.98 (tt, *J* = 7.3, 1.2 Hz, 2H), 5.04 (s, 1H), 4.17 (t, *J* = 8.6 Hz, 1H), 1.61 (d, *J* = 8.6 Hz, 1H), 1.44 (s, 18H), 1.09 (s, 12H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.8, 148.0, 145.4, 142.0, 137.3, 135.3, 129.0, 128.5, 124.6, 124.2, 123.6, 122.2, 83.0, 46.1, 34.4,

30.3, 24.6, 24.6.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 34.10.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>46</sub>BNO<sub>3</sub>Na: 626.3776, found: 626.3773.

**2,6-di-*tert*-butyl-4-(1-(4-(piperidin-1-yl)phenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3p)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.18 (d, *J* = 8.5 Hz, 2H), 7.09 (s, 2H), 6.86 (d, *J* = 8.5 Hz, 2H), 4.98 (s, 1H), 4.11 (t, *J* = 8.7 Hz, 1H), 3.17 – 3.01 (m, 4H), 1.79 – 1.67 (m, 4H), 1.57 (d, *J* = 8.7 Hz, 2H), 1.59 – 1.52 (m, 2H), 1.41 (s, 18H), 1.05 (s, 6H), 1.03 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.7, 150.4, 138.5, 137.5, 135.2, 128.0, 124.1, 116.7, 82.9, 51.2, 45.9, 34.3, 30.3, 25.9, 24.7, 24.6,

24.6.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.78.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>33</sub>H<sub>50</sub>BNO<sub>3</sub>Na: 542.3776, found: 542.3779.

**2,6-di-*tert*-butyl-4-(1-(4-morpholinophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3q)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.22 (d, *J* = 8.5 Hz, 2H), 7.09 (s, 2H), 6.84 (d, *J* = 8.5 Hz, 2H), 5.00 (s, 1H), 4.13 (t, *J* = 8.6 Hz, 1H), 3.93 – 3.81 (m, 4H), 3.11 (dd, *J* = 5.8, 3.8 Hz, 4H), 1.58 (d, *J* = 8.6 Hz, 2H), 1.42 (s, 18H), 1.05 (s, 6H), 1.04 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.7, 149.3, 139.3, 137.2, 135.3, 128.1, 124.1, 115.8, 82.9, 67.0, 49.8, 45.9, 34.3, 30.3, 24.6, 24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 35.03.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>48</sub>BNO<sub>4</sub>Na: 544.3569, found: 544.3572.

**2,6-di-*tert*-butyl-4-(1-(2-chlorophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3r)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.32 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.21 (td, *J* = 7.6, 1.4 Hz, 1H), 7.16 (s, 2H), 7.08 (td, *J* = 7.7, 1.7 Hz, 1H), 5.02 (s, 1H), 4.74 (t, *J* = 8.7 Hz, 1H), 1.64 (dd, *J* = 15.2, 8.7 Hz, 1H), 1.57 (dd, *J* = 15.2, 8.7 Hz, 1H), 1.42 (s, 18H), 1.03 (s, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.9, 144.5, 135.5, 135.2, 133.7, 129.4, 128.3, 126.79, 126.75, 124.5, 83.0, 42.2, 34.3, 30.3, 24.48, 24.46.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.68.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>40</sub>ClBO<sub>3</sub>Na: 493.2651, found: 493.2656.

**2,6-di-*tert*-butyl-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(o-tolyl)ethyl)phenol (3s)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.18 (td, *J* = 7.4, 1.8 Hz, 1H), 7.12 – 7.03 (m, 2H), 7.09 (s, 2H), 4.99 (s, 1H), 4.40 (t, *J* = 8.6 Hz, 1H), 2.40 (s, 3H), 1.60 (d, *J* = 8.6 Hz, 2H), 1.41 (s, 18H), 1.05 (s, 6H), 1.01 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.6, 145.0, 136.7, 135.8, 135.2, 130.0, 126.6, 125.9, 125.5, 124.3, 82.9, 42.0, 34.3, 30.3, 24.6, 24.5, 20.1.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.90.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>43</sub>BO<sub>3</sub>Na: 473.3197, found: 473.3203.

**2,6-di-*tert*-butyl-4-(1-(2-methoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3t)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.30 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.19 (s, 2H), 7.14 (td, *J* = 7.8, 1.7 Hz, 1H), 6.91 (td, *J* = 7.5, 1.1 Hz, 1H), 6.83 (dd, *J* = 8.1, 1.1 Hz, 1H), 4.98 (s, 1H), 4.66 (t, *J* = 8.8 Hz, 1H), 3.84 (s, 3H), 1.61 (dd, *J* = 16.9, 8.8 Hz, 2H), 1.43 (s, 18H), 1.02 (s, 6H), 1.02 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 156.7, 151.6, 136.6, 135.8, 134.9, 127.5, 126.5, 124.6, 120.4, 110.4, 82.8, 55.3, 38.9, 34.3, 30.4, 24.51, 24.45.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 34.61.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>43</sub>BO<sub>4</sub>Na: 489.3147, found: 489.3151.

**3-(1-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)benzonitrile (3u)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.59 (t, *J* = 1.8 Hz, 1H), 7.54 (dt, *J* = 7.9, 1.6 Hz, 1H), 7.45 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 1H), 7.05 (s, 2H), 5.09 (s, 1H), 4.23 (t, *J* = 8.5 Hz, 1H), 1.59 (dd, *J* = 8.5, 4.0 Hz, 2H), 1.43 (s, 18H), 1.07 (s, 6H), 1.06 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 152.2, 148.8, 135.7, 135.4, 132.1, 131.3, 129.5, 128.9, 124.1, 119.2, 112.0, 83.2, 46.2, 34.3, 30.3, 24.6, 24.5.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 34.12.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>BN<sub>2</sub>O<sub>3</sub>Na: 484.2993, found: 484.2999.

**2,6-di-*tert*-butyl-4-(1-(3-methoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3v)**



**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.19 (t, *J* = 7.9 Hz, 1H), 7.12 (s, 2H), 6.93 (dt, *J* = 7.7, 1.1 Hz, 1H), 6.87 (t, *J* = 2.1 Hz, 1H), 6.73 – 6.67 (m, 1H), 5.01 (s, 1H), 4.17 (t, *J* = 8.6 Hz, 1H), 3.79 (s, 3H), 1.60 (d, *J* = 8.6 Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.04 (s, 6H).


**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 159.4, 151.9, 149.1, 136.7, 135.3, 129.0, 124.2, 120.0, 113.4, 111.0, 82.9, 55.1, 46.8, 34.3, 30.3, 24.6,

24.5.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 34.66.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>43</sub>BO<sub>4</sub>Na: 489.3147, found: 489.3154.

**2,6-di-*tert*-butyl-4-(1-(3,4-dimethoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3w)**



**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.11 (s, 2H), 6.88 (d, *J* = 2.1 Hz, 1H), 6.86 (dd, *J* = 8.2, 2.1 Hz, 1H), 6.79 (d, *J* = 8.2 Hz, 1H), 5.01 (s, 1H), 4.14 (t, *J* = 8.6 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 1.59 (dd, *J* = 8.6, 1.8 Hz, 2H), 1.42 (s, 18H), 1.05 (s, 12H).


**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.8, 148.5, 147.0, 140.1, 137.2, 135.3, 124.0, 119.4, 111.1, 111.0, 83.0, 55.9, 55.7, 46.3, 34.3, 30.3,

24.60, 24.57.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 34.03.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>45</sub>BO<sub>5</sub>Na: 519.3252, found: 519.3258.

**2,6-di-*tert*-butyl-4-(1-(2,4-dimethoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3x)**



**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.11 (s, 2H), 6.88 (d, *J* = 2.1 Hz, 1H), 6.86 (dd, *J* = 8.2, 2.1 Hz, 1H), 6.79 (d, *J* = 8.2 Hz, 1H), 5.01 (s, 1H), 4.14 (t, *J* = 8.6 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 1.59 (dd, *J* = 8.6, 1.7 Hz, 2H), 1.42 (s, 18H), 1.05 (s, 12H).


**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.8, 148.4, 146.9, 140.0, 137.1, 135.3, 124.0, 119.3, 111.1, 111.0, 82.9, 55.9, 55.7, 46.3, 34.3, 30.3,

24.59, 24.55.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.86.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>45</sub>BO<sub>5</sub>Na: 519.3252, found: 519.3259.

**2,6-di-*tert*-butyl-4-(1-(2,4-dimethylphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3y)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.30 – 7.25 (m, 1H), 7.09 (s, 2H), 6.99 (dd, *J* = 7.9, 1.9 Hz, 1H), 6.91 (d, *J* = 1.9 Hz, 1H), 4.97 (s, 1H), 4.36 (t, *J* = 8.6 Hz, 1H), 2.37 (s, 3H), 2.27 (s, 3H), 1.58 (d, *J* = 8.6 Hz, 2H), 1.41 (s, 18H), 1.04 (s, 6H), 1.02 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.6, 142.1, 136.9, 135.4, 135.1, 134.7, 130.8, 126.5, 126.4, 124.3, 82.9, 41.7, 34.3, 30.3, 24.6, 24.5,

20.8, 20.0.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 35.21.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>45</sub>BO<sub>3</sub>Na: 487.3354, found: 487.3360.

**2,6-di-*tert*-butyl-4-(1-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3z)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.09 (s, 2H), 6.83 – 6.78 (m, 2H), 6.77 – 6.74 (m, 1H), 5.00 (s, 1H), 4.27 – 4.20 (m, 4H), 4.08 (t, *J* = 8.6 Hz, 1H), 1.55 (dd, *J* = 8.6, 6.2 Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.04 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.8, 143.0, 141.4, 141.1, 136.9, 135.3, 124.1, 120.3, 116.7, 116.2, 82.9, 64.4, 64.3, 46.0, 34.3, 30.3,

24.6, 24.5.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.45.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>43</sub>BO<sub>5</sub>Na: 517.3096, found: 517.3102.

**2,6-di-*tert*-butyl-4-(1-(naphthalen-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3aa)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.84 – 7.80 (m, 1H), 7.79 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.78 – 7.76 (m, 1H), 7.74 (d, *J* = 8.5 Hz, 1H), 7.48 – 7.39 (m, 3H), 7.16 (s, 2H), 5.03 (s, 1H), 4.38 (t, *J* = 8.5 Hz, 1H), 1.71 (dd, *J* = 8.5, 5.3 Hz, 2H), 1.43 (s, 18H), 1.03 (s, 6H), 1.03 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.9, 144.8, 136.8, 135.4, 133.5, 132.0, 127.7, 127.7, 127.5, 126.8, 125.6, 125.2, 125.0, 124.3, 83.0, 46.7, 34.3, 30.3, 24.57, 24.55.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 34.99.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>43</sub>BO<sub>3</sub>Na: 503.3197, found: 503.3202.

**2,6-di-*tert*-butyl-4-(1-(naphthalen-1-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3ab)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.35 (d, *J* = 8.5 Hz, 1H), 7.84 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.70 (d, *J* = 7.9 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.48 – 7.41 (m, 2H), 7.18 (s, 2H), 5.05 (t, *J* = 8.5 Hz, 1H), 5.00 (s, 1H), 1.76 (dd, *J* = 15.3, 8.5 Hz, 1H), 1.70 (dd, *J* = 15.3, 8.5 Hz, 1H), 1.40 (s, 18H), 1.02 (s, 6H), 0.97 (s, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.8, 143.2, 136.6, 135.2, 133.9, 131.7, 128.6, 126.4, 125.5, 125.4, 125.1, 124.5, 124.2, 124.1, 82.9, 41.5, 34.3, 30.3, 24.50, 24.47.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>32</sub>H<sub>43</sub>BO<sub>3</sub>Na: 503.3197, found: 503.3206.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 34.86.

**2,6-di-*tert*-butyl-4-(1-(6-methoxynaphthalen-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3ac)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.70 (d, *J* = 9.1 Hz, 1H), 7.69 (d, *J* = 2.4 Hz, 1H), 7.64 (d, *J* = 8.5 Hz, 1H), 7.40 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.15 (s, 2H), 7.12 (dd, *J* = 8.8, 2.5 Hz, 1H), 7.10 (d, *J* = 2.5 Hz, 1H), 5.02 (s, 1H), 4.34 (t, *J* = 8.6 Hz, 1H), 3.92 (s, 3H), 1.68 (dd, *J* = 8.6, 7.2 Hz, 2H), 1.42 (s, 18H), 1.03 (s, 12H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 157.1, 151.8, 142.5, 137.0, 135.3, 132.9, 129.2, 129.0, 127.3, 126.6, 125.1, 124.3, 118.3, 105.6, 83.0, 55.2, 46.5, 34.3, 30.3, 24.58, 24.56.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 34.35.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>33</sub>H<sub>45</sub>BO<sub>4</sub>Na: 539.3303, found: 539.3300.

**2,6-di-*tert*-butyl-4-(1-(quinoline-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3ad)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 8.89 (d, *J* = 2.3 Hz, 1H), 8.06 (d, *J* = 8.4 Hz, 1H), 8.02 (d, *J* = 2.2 Hz, 1H), 7.79 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.65 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.52 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 7.14 (s, 2H), 5.08 (s, 1H), 4.42 (t, *J* = 8.5 Hz, 1H), 1.72 (d, *J* = 8.5 Hz, 2H), 1.42 (s, 18H), 1.04 (s, 6H), 1.04 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 152.2, 152.0, 146.5, 140.1, 135.8, 135.5, 132.7, 128.9, 128.5, 128.1, 127.6, 126.4, 124.2, 83.2, 44.3, 34.3, 30.3, 24.58, 24.56.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.50.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>31</sub>H<sub>42</sub>BO<sub>4</sub>Na: 510.3150, found: 510.3153.

**2,6-di-*tert*-butyl-4-(1-(pyridin-3-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3ae)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 8.59 (d, *J* = 2.3 Hz, 1H), 8.41 (dd, *J* = 4.9, 1.6 Hz, 1H), 7.59 (dt, *J* = 7.9, 2.0 Hz, 1H), 7.20 (ddd, *J* = 7.9, 4.8, 0.9 Hz, 1H), 7.08 (s, 2H), 5.07 (s, 1H), 4.22 (t, *J* = 8.6 Hz, 1H), 1.61 (dd, *J* = 8.6, 3.3 Hz, 2H), 1.42 (s, 18H), 1.06 (s, 6H), 1.05 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 152.1, 149.4, 147.1, 142.5, 135.7, 135.6, 134.8, 124.1, 123.2, 83.2, 44.2, 34.3, 30.3, 24.6, 24.5.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.86.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>27</sub>H<sub>40</sub>BNO<sub>3</sub>Na: 460.2993, found: 460.2998.

**4-(1-(benzo[b]thiophen-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-2,6-di-*tert*-butylphenol (3af)**




**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.84 (ddd, *J* = 7.3, 5.5, 1.6 Hz, 2H), 7.36 – 7.29 (m, 2H), 7.24 (d, *J* = 0.9 Hz, 1H), 7.16 (s, 2H), 5.01 (s, 1H), 4.55 (t, *J* = 8.5 Hz, 1H), 1.76 (dd, *J* = 15.3, 8.5 Hz, 1H), 1.66 (dd, *J* = 15.3, *J* = 8.5 Hz, 1H), 1.41 (s, 18H), 1.08 (s, 6H), 1.01 (s, 6H).

**<sup>13</sup>C NMR** (125 MHz, CDCl<sub>3</sub>) δ 151.9, 142.3, 140.6, 138.7, 135.7, 135.4, 124.2, 123.9, 123.5, 122.6, 122.6, 120.9, 83.0, 40.7, 34.3, 30.3, 24.6, 24.5.

**<sup>11</sup>B NMR** (160 MHz, CDCl<sub>3</sub>) δ 33.4.

**HRMS:** (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>41</sub>BO<sub>3</sub>SNa: 515.2762, found: 515.2768.

**2,6-di-*tert*-butyl-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(thiophen-2-yl)ethylphenol (3ag)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.14 (s, 2H), 7.10 (dd, *J* = 5.1, 1.2 Hz, 1H), 6.89 (dd, *J* = 5.1, 3.5 Hz, 1H), 6.82 (dt, *J* = 3.5, 1.2 Hz, 1H), 5.04 (s, 1H), 4.41 (t, *J* = 8.5 Hz, 1H), 1.69 (dd, *J* = 15.2, 8.5 Hz, 1H), 1.63 (dd, *J* = 15.2, 8.5 Hz, 1H), 1.43 (s, 18H), 1.07 (s, 12H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 152.4, 152.1, 136.5, 135.4, 126.3, 124.0, 123.1, 122.9, 83.1, 42.3, 34.3, 30.3, 24.59, 24.56.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.71.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>26</sub>H<sub>39</sub>O<sub>3</sub>Na: 465.2605, found: 465.2613.

**4-(1-(benzo[b]furan-2-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)-2,6-di-*tert*-butylphenol (3ah)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.51 – 7.45 (m, 1H), 7.43 – 7.38 (m, 1H), 7.23 – 7.14 (m, 2H), 7.17 (s, 2H), 6.37 (d, *J* = 1.0 Hz, 1H), 5.08 (s, 1H), 4.31 (t, *J* = 8.3 Hz, 1H), 1.72 (dd, *J* = 15.4, 8.3 Hz, 1H), 1.56 (dd, *J* = 15.4, 8.3 Hz, 1H), 1.44 (s, 18H), 1.13 (s, 6H), 1.11 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 163.5, 154.8, 152.4, 135.5, 133.9, 128.9, 124.4, 123.0, 122.2, 120.3, 110.9, 101.5, 83.2, 41.0, 34.4, 30.3,

24.7, 24.6.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.51.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>41</sub>BO<sub>4</sub>Na: 499.2990, found: 499.2997.

**2,6-di-*tert*-butyl-4-(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)phenol (3ai)**




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.06 (s, 2H), 5.01 (s, 1H), 2.98 (dp, *J* = 8.7, 6.9 Hz, 1H), 1.45 (s, 18H), 1.28 (d, *J* = 6.9 Hz, 3H), 1.18 (s, 12H), 1.16 (d, *J* = 8.7 Hz, 2H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.6, 139.7, 135.3, 123.1, 82.9, 35.7, 34.4, 30.4, 25.3, 24.8, 24.7.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.99.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>39</sub>BO<sub>3</sub>Na: 397.2884, found: 397.2887.

**2,6-diisopropyl-4-(1-(4-methoxyphenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)phenol (3aj)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.20 (d, *J* = 8.7 Hz, 2H), 6.97 (s, 2H), 6.81 (d, *J* = 8.7 Hz, 2H), 4.63 (s, 1H), 4.17 (t, *J* = 8.6 Hz, 1H), 3.78 (s, 3H), 3.12 (hept, *J* = 6.9 Hz, 2H), 1.58 (d, *J* = 8.6 Hz, 2H), 1.25 (d, *J* = 6.9 Hz, 6H), 1.24 (d, *J* = 6.9 Hz, 7H), 1.07 (s, 6H), 1.05 (s, 6H).


<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 157.5, 148.0, 139.6, 138.6, 133.1, 128.4, 122.6, 113.5, 83.0, 55.2, 45.6, 27.3, 24.7, 24.6, 24.5, 22.8, 22.7.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.89.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>27</sub>H<sub>39</sub>BO<sub>4</sub>Na: 461.2834, found: 461.2834.

**2,6-di-*tert*-butyl-4-(2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-yl)phenol (5a)**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.14 (s, 2H), 4.98 (s, 1H), 1.68 (dh, *J* = 20.9, 7.4 Hz, 3H), 1.45




(s, 18H), 1.40 (s, 3H), 1.30 (d,  $J = 14.9$  Hz, 2H), 1.15 (d,  $J = 14.9$  Hz, 1H), 1.10 (s, 6H), 1.06 (s, 6H), 0.72 (t,  $J = 7.4$  Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 151.1, 139.9, 134.4, 122.8, 82.5, 39.3, 38.0, 34.5, 30.5, 26.5, 24.8, 24.5, 9.2.

<sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ 33.57.


HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>25</sub>H<sub>43</sub>BO<sub>3</sub>Na: 425.3197, found: 425.3192.

## V. Synthesis of compound 7



To a solution **3a** (23.3 mg, 0.05 mmol) in anhydrous THF (0.5 mL) was added a solution of NaH<sub>2</sub>PO<sub>4</sub> (15.0 mg, 0.125 mmol, 2.5 equiv) in water (0.5 mL). The reaction mixture was then cooled to 0 °C and H<sub>2</sub>O<sub>2</sub> (30% wt% in H<sub>2</sub>O, 0.5 mL) was added. After stirring at room temperature for additional 24 hours, the reaction was quenched with saturated NH<sub>4</sub>Cl and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 3/1) to afford the pure product.

### 2,6-di-tert-butyl-4-(2-hydroxy-1-(4-methoxyphenyl)ethyl)phenol (7)




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.23 (d,  $J = 8.7$  Hz, 2H), 7.07 (s, 2H), 6.90 (d,  $J = 8.7$  Hz, 2H), 5.14 (s, 1H), 4.10 (d,  $J = 1.6$  Hz, 3H), 3.82 (s, 3H), 1.51 (b, 1H), 1.44 (s, 18H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 158.3, 152.5, 136.0, 133.9, 131.8, 129.2, 124.7, 114.0, 66.7, 55.2, 52.9, 34.4, 30.3.


HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>32</sub>O<sub>3</sub>Na: 379.2244, found: 379.2249.

## VI. Synthesis of compound 9



An oven-dried Schlenk tube was charged with compound **3a** (23.3 mg, 0.05 mmol), Pd(OAc)<sub>2</sub> (1.7 mg, 15 mol %), BINAP (4.7 mg, 15 mol %), and KOH (42.0 mg, 0.75 mol, 15 equiv). The tube was sealed, degased and refilled with N<sub>2</sub> for 3 times. Then a solution of 1-bromo-4-methylbenzene (25.7 mg, 0.15 mmol, 3 equiv) in THF (1.0 mL) and water (0.1 mL) were injected into the tube via syringes. The tube was heated at 100 °C for 12 hours. After completion, the reaction mixture was filtered through a pad of Celite and Na<sub>2</sub>SO<sub>4</sub>. The filtrate was washed with ethyl acetate for 3 times (3 × 10 mL). The combined organic solvents were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 20/1) to afford the pure product.

**2,6-di-tert-butyl-4-(1-(4-methoxyphenyl)-2-(p-tolyl)ethyl)phenol (9)**



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.15 (d, *J* = 8.7 Hz, 2H), 7.00 (d, *J* = 7.8 Hz, 2H), 6.97 (s, 2H), 6.89 (d, *J* = 7.8 Hz, 2H), 6.82 (d, *J* = 8.7 Hz, 2H), 5.04 (s, 1H), 4.08 (t, *J* = 7.8 Hz, 1H), 3.80 (s, 3H), 3.25 (qd, *J* = 13.5, 7.8 Hz, 2H), 2.30 (s, 3H), 1.41 (s, 18H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 157.7, 151.8, 137.7, 137.1, 135.6, 135.3, 135.0, 129.0, 129.0, 128.6, 124.4, 113.5, 55.2, 52.4, 42.7, 34.3, 30.3, 21.0.

HRMS: (ESI<sup>+</sup>) [M+Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>38</sub>O<sub>2</sub>Na: 453.2764, found: 453.2766.

## VII. NMR Spectra

Please refer to next pages

